Bile Duct Cancer (Cholangiocarcinoma)
A rare but serious cancer of the bile ducts. This guide explains types, risk factors, diagnosis, staging, treatment options including surgery and chemotherapy, and questions to ask your care team.
Quick Overview
New Cases Per Year
Approximately 12,500 new cases diagnosed in the United States annually. Bile duct cancer accounts for about 3% of all gastrointestinal cancers. [NCI, 2024]
Relatively Uncommon
Bile duct cancer is one of the rarer cancers, which means fewer treatment specialists but increasing clinical trial options. [ACS, 2024]
Typically Diagnosed in Older Adults
Median age at diagnosis is around 70 years. It is rarely diagnosed before age 40, though it can occur at any age. [NCI, 2024]
Primary Sclerosing Cholangitis Risk
People with primary sclerosing cholangitis (PSC), a chronic bile duct condition, have a 400-fold increased risk of bile duct cancer. [ACS, 2024]
What Is Bile Duct Cancer?
Bile duct cancer, medically known as cholangiocarcinoma, develops in the epithelial cells (the inner lining) of the bile ducts. The bile ducts are small tubes that carry bile — a digestive liquid produced by the liver — to the small intestine where it helps break down fats. When cancer develops, these tubes become narrow, blocking the flow of bile and causing a backup of bilirubin into the bloodstream, leading to jaundice (yellowing of the skin and eyes). [NCI, 2024]
Bile duct cancer is divided into two main types based on location:
- Intrahepatic cholangiocarcinoma — arises inside the liver, accounts for about 10-15% of cases
- Extrahepatic cholangiocarcinoma — arises outside the liver (in the common bile duct or junction of bile ducts), accounts for about 85-90% of cases
Bile duct cancer is often diagnosed at an advanced stage because early symptoms are minimal and the tumor can grow silently. This makes understanding your diagnosis, staging, and treatment options especially important for effective care.
Types of Bile Duct Cancer
The location and histologic subtype of bile duct cancer determine treatment strategy and prognosis.
Intrahepatic Cholangiocarcinoma
Develops within the liver parenchyma (tissue) in the small bile ducts. Accounts for 10-15% of cholangiocarcinomas. Often presents as a solitary mass that may be confused with hepatocellular carcinoma. Treatment often involves hepatic resection (removal of part of the liver) or liver transplantation. [ACS, 2024]
Extrahepatic Cholangiocarcinoma
Develops in the bile ducts outside the liver — including the distal common bile duct, hepatic ducts, and junction of hepatic ducts. Accounts for 85-90% of cases. Presents with obstructive jaundice from the tumor blocking bile flow. Can often be resected surgically if detected early enough. [NCI, 2024]
Adenocarcinoma
The most common histologic type of bile duct cancer (90%+). Develops from glandular epithelial cells lining the bile ducts. Generally aggressive and has a variable prognosis depending on stage and degree of differentiation. [ACS, 2024]
Squamous Cell & Other Rare Types
Squamous cell carcinoma and mucinous carcinomas of the bile ducts are rare, accounting for less than 5% of cases. These have different biologic behaviors and may require specialized treatment approaches. Always discuss your specific histology with your oncology team. [NCI, 2024]
Risk Factors
Understanding your risk factors helps guide screening decisions and preventive measures when applicable.
Primary Sclerosing Cholangitis (PSC)
The strongest risk factor for bile duct cancer. PSC is a chronic autoimmune disease causing progressive inflammation and scarring of the bile ducts. People with PSC have a 400-fold increased risk of cholangiocarcinoma. Regular screening and surveillance are recommended. [ACS, 2024]
Chronic Biliary Tract Infections
Chronic or recurrent infections, particularly from parasites like liver flukes (common in Southeast Asia), increase bile duct cancer risk. Bile duct stones and strictures (narrowing) that create stasis also increase risk by causing repeated inflammation. [NCI, 2024]
Cirrhosis & Liver Disease
Cirrhosis from any cause (hepatitis B, hepatitis C, alcohol) increases bile duct cancer risk. The chronic inflammation and regeneration of liver tissue creates an environment favorable for malignant transformation. [ACS, 2024]
Choledochal Cysts
Congenital cysts of the bile ducts increase the risk of cholangiocarcinoma, with lifetime risk estimates of 5-20% depending on the cyst type. Prophylactic surgical resection is sometimes recommended. [NCI, 2024]
Inflammatory Bowel Disease
Patients with ulcerative colitis or Crohn's disease, especially those with concurrent PSC, have significantly increased bile duct cancer risk. Regular surveillance is recommended. [ACS, 2024]
Age & Gender
Risk increases with age, with median diagnosis around 70 years. Men are slightly more likely to develop bile duct cancer than women. [NCI, 2024]
Symptoms of Bile Duct Cancer
Early-stage bile duct cancer often causes no symptoms. When symptoms do appear, they typically relate to bile duct obstruction.
How Bile Duct Cancer Is Diagnosed
Diagnosis typically involves blood tests, imaging studies, and sometimes endoscopic tissue sampling.
Blood Tests & Liver Function
Initial blood work shows elevated bilirubin (conjugated), elevated liver enzymes (ALP, GGT, transaminases), and often elevated CA 19-9 (a tumor marker). These findings suggest bile duct obstruction but are not specific for cancer. [ACS, 2024]
Imaging: CT & MRI/MRCP
High-resolution CT scans with contrast help visualize the tumor size, location, and extent of spread. MRI with magnetic resonance cholangiopancreatography (MRCP) provides detailed imaging of the bile ducts and can show the exact location of obstruction. These are the primary imaging modalities. [NCI, 2024]
Endoscopic Retrograde Cholangiopancreatography (ERCP)
An endoscopic procedure allowing direct visualization of the bile ducts and biopsy sampling. During ERCP, a stent (plastic tube) can also be placed to relieve biliary obstruction and allow bile drainage, providing symptomatic relief. [ACS, 2024]
Endoscopic Ultrasound (EUS)
High-resolution ultrasound performed via an endoscope allows close-up imaging of the bile ducts and precise biopsy sampling under real-time visualization. Often combines imaging with tissue diagnosis. [NCI, 2024]
Biopsy & Pathology
Tissue diagnosis is essential. Brushings or biopsies obtained during ERCP or EUS are examined under a microscope to confirm adenocarcinoma and rule out benign strictures or other conditions. This is the definitive diagnosis. [ACS, 2024]
Staging System (TNM)
Bile duct cancer is staged using the TNM system. Staging determines treatment options and prognosis.
Stage I — Localized
Tumor confined to the bile duct without extension into surrounding tissues or involvement of major blood vessels. No lymph node involvement. These tumors are potentially resectable and carry the best prognosis. 5-year survival approximately 30-50%. [ACS, 2024]
Stage II — Regional Involvement
Tumor extends into surrounding tissues or involves major blood vessels, but without distant metastasis or distant lymph node involvement. May still be resectable depending on exact extent. 5-year survival approximately 15-30%. [NCI, 2024]
Stage III — Regional Lymph Node Involvement
Cancer involves regional lymph nodes (regional nodes around the liver, pancreas, or bile ducts) regardless of whether the primary tumor is resectable. Distant metastasis is absent. Treatment often involves chemotherapy and palliative surgery. 5-year survival approximately 5-15%. [ACS, 2024]
Stage IV — Distant Metastasis
Cancer has spread to distant organs (peritoneum, lungs, bone, brain) or distant lymph nodes. Typically not surgically resectable. Treatment focuses on chemotherapy and symptom management. 5-year survival less than 5%. [NCI, 2024]
Treatment for Bile Duct Cancer
Treatment depends on tumor stage, location, resectability, and overall health. Most patients benefit from multimodal therapy combining surgery, chemotherapy, and supportive care.
Surgery: Resection & Transplantation
Surgery offers the only potential cure for bile duct cancer. For extrahepatic tumors, the goal is resection (removal) of the tumor along with nearby lymph nodes and affected bile ducts. For intrahepatic tumors, hepatic resection (removal of part of the liver) may be performed. In select cases of early intrahepatic cholangiocarcinoma with underlying cirrhosis, liver transplantation may be considered. [NCCN, 2024]
Palliative Stenting
When the tumor cannot be surgically removed, a biliary stent (plastic or metal tube) is placed endoscopically or percutaneously to bypass the obstruction and allow bile drainage. This relieves jaundice and itching, improving quality of life. Stent patency (staying open) may require periodic replacement. [ACS, 2024]
Chemotherapy
The chemotherapy combination of gemcitabine and cisplatin is the standard first-line treatment for advanced bile duct cancer. Clinical trials have shown this combination improves survival in patients with unresectable or metastatic disease. Chemotherapy is typically given intravenously every 3-4 weeks for 6-8 cycles. [NCCN, 2024]
Radiation Therapy
External beam radiation or brachytherapy (internal radiation) may be used in select cases, either as primary treatment for unresectable disease or adjuvantly after surgery. Intensity-modulated radiation therapy (IMRT) minimizes damage to surrounding tissues. [NCI, 2024]
Targeted Therapy & Immunotherapy
Research is advancing targeted therapies for specific mutations (FGFR2 fusions, IDH1 mutations) found in some bile duct cancers. Immunotherapy checkpoint inhibitors are being studied in clinical trials. These options may become standard as evidence accumulates. [NCCN, 2024]
Clinical Trials
Clinical trials investigating new drug combinations, targeted therapies, and immunotherapy approaches are critical resources for bile duct cancer patients. Discuss trial eligibility with your oncology team. Search ClinicalTrials.gov for current opportunities. [NCI, 2024]
Side Effects of Treatment
Cancer treatments have side effects. Knowing what to expect allows you and your care team to manage them proactively.
Surgical Side Effects
Pain at the incision site, infection risk, temporary bowel dysfunction, and possible need for permanent or temporary drainage tubes. Recovery typically takes 6-8 weeks.
Chemotherapy Toxicity
Nausea, vomiting, fatigue, decreased blood cell counts (anemia, low white cells, low platelets), mouth sores, and diarrhea. Anti-nausea medications help manage these effects.
Radiation Side Effects
Skin irritation, nausea, fatigue, and diarrhea during treatment. Potential for long-term effects on surrounding organs if extensive radiation is given.
Stent Complications
Stent blockage, infection (cholangitis), or migration. Signs include fever, worsening jaundice, or abdominal pain — report these immediately to your team.
Living With Bile Duct Cancer
Survivorship care, symptom management, and emotional support are integral parts of your cancer journey.
Follow-Up Monitoring
After treatment, regular surveillance with CT or MRI imaging and CA 19-9 blood tests helps detect early recurrence. Most follow-up occurs every 2-3 months initially, then less frequently as you move further from treatment. [NCCN, 2024]
Nutritional Support
Bile duct cancer and its treatments can affect digestion and fat absorption. A registered dietitian can help optimize nutrition and manage diarrhea or other digestive symptoms. Fat-soluble vitamin supplementation may be needed. [ACS, 2024]
Mental Health & Emotional Support
The diagnosis of a rare cancer can be emotionally overwhelming. Anxiety, depression, and fear of recurrence are common. Counseling, support groups, and psychiatric medications can help. Many cancer centers offer survivorship programs addressing psychological needs. [NCI, 2024]
Specialized Care Team
Because bile duct cancer is rare, consider seeking care at a comprehensive cancer center or center of excellence with significant experience in biliary cancers. Hepatobiliary surgeons and medical oncologists experienced in this disease provide optimized treatment. [ACS, 2024]
Questions to Ask Your Care Team
Come prepared with questions about your diagnosis, treatment options, and supportive care.
About My Diagnosis
About Treatment Options
Sources & References
Every claim on this page is grounded in clinical guidelines and peer-reviewed research.
-
American Cancer Society (ACS). "Bile Duct Cancer Overview." Cancer.org. Accessed 2024.
https://www.cancer.org/cancer/bile-duct-cancer.html -
National Cancer Institute (NCI). "Bile Duct Cancer Treatment (PDQ) — Patient Version." Cancer.gov. Accessed 2024.
https://www.cancer.gov/types/bile-duct -
National Comprehensive Cancer Network (NCCN). "NCCN Clinical Practice Guidelines in Oncology: Bile Duct and Hepatocellular Carcinoma." Version 1.2024.
https://www.nccn.org/guidelines/ -
World Health Organization (WHO). "Cholangiocarcinoma." WHO Global Cancer Observatory. Accessed 2024.
https://gco.iarc.fr/
Last reviewed: February 2025. This page is regularly reviewed and updated as new evidence becomes available. StopMyCancer is not affiliated with any of the organizations cited above.